Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has issued an update.
SynAct Pharma AB announced the departure of its CFO, Björn Westberg, who will leave once a successor is appointed. During his tenure, Westberg secured financing that extended the company’s financial runway into 2027 and contributed to the development of SynAct’s pipeline, including the lead compound resomelagon (AP1189) in Phase 2b development for Rheumatoid Arthritis. The company is actively searching for a new CFO to continue its strategic growth and development.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, specializing in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activities, aiming to help patients achieve immune balance.
Average Trading Volume: 172,975
Technical Sentiment Signal: Hold
Current Market Cap: SEK973.8M
For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.